Arrowhead Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Good afternoon. My name is Gena Wang, SMID-cap biotech analyst of Barclays. It's my great pleasure to introduce our next speaker, Bruce Given, Chief Operating Officer and Head of R&D of Arrowhead.
Good afternoon. Thank you for the invitation to speak. I've been asked to move very quickly through the slides so we have plenty of time for Q&A. So I'll go right ahead here, assuming I can get this to advance. There we go. Because I'm moving quickly, I would encourage any of you to be sure to take a look at our forward-looking statement.
So we're going to talk today about our platform, which is the TRiM platform. It's in cartoon form. It's quite simple. It's a double-stranded siRNA molecule that's been heavily modified to survive the body's many defense mechanisms against such molecules. And then we -- these double-stranded RNA molecules do not tend to traverse plasma membranes easily. So to get into cells, we target them to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
